25 articles
Oral probiotics cut severe mouth sores during cancer treatment by 39%, with multi-strain formulas proving most effective, a review of 12 trials finds.
Brushing teeth twice daily cuts cavity risk in half, a Nigerian study finds, while poor oral hygiene raises cavity risk by 76%.
An AI system called XunZi analyzed 24 million studies to identify new Parkinson's disease targets, validating them in mouse models with promising results.
A liquid treatment called silver diamine fluoride stopped tooth decay in over half of baby teeth treated, with no drilling, no anesthesia, and no serious.
Cervical cancer is striking younger women at later stages, even as overall cases decline, revealing critical gaps in screening and prevention efforts.
Pig kidney transplants are nearing human trials, with experts tackling safety and longevity questions for the 100,000+ Americans awaiting a kidney.
Swiss researchers linked cancer drug approvals to real patient outcomes for the first time, revealing which treatments truly deliver survival benefits.
A minimally invasive knee osteoarthritis treatment called genicular artery embolization cut pain by 57% in patients who failed conventional therapies.
An NIH clinical trial found lifestyle changes beat medication for prediabetes, cutting risk of diabetes, heart disease, and kidney problems simultaneously.
Dupilumab shows promise for eosinophilic gastritis, while the FDA approves the first steroid-free topical psoriasis cream for children as young as 2.
NIH-funded medical research now costs scientists up to $12,850 per paper to publish openly, forcing researchers to choose between prestige journals and.
The FDA's Operation TrialBlazer is overhauling drug development rules, cutting delays of up to 12 months and replacing animal tests with AI-powered models.
Adaptive deep brain stimulation cuts freezing of gait in Parkinson's patients, but FDA approval hinges on validating the algorithm, not the hardware.
Adding durvalumab to BCG improved bladder cancer survival rates, but caused serious side effects in 21% of patients versus just 4% with BCG alone.
A decades-old heart drug, spironolactone, showed promise for improving working memory in schizophrenia patients, addressing a cognitive gap no current.
MetALD, a liver disease combining alcohol use and metabolic dysfunction, affects millions and progresses faster than either condition alone.
Ultrasound-guided carpal tunnel surgery lets most patients return to work in four days, with zero complications reported across the largest U.S. study.
Federal agencies are replacing animal testing with lab-grown organs and AI models that better predict human drug responses and reduce failures.
A new OMB proposal could give political appointees control over medical research funding, replacing scientist-led peer review with political decisions.
FDA approves first major U.S. trial of ozone injection for herniated discs, testing whether this minimally invasive treatment can help 300 patients avoid.
Repatha cholesterol drug cuts heart attack risk by 29% in high-risk diabetes patients when added to statins, new clinical trial data reveals.
Multi-arm platform trials could end neurodegenerative disease research's 99.6% failure rate by testing multiple treatments simultaneously.
Semaglutide users face double the risk of rare vision-threatening condition NAION, though absolute risk remains low at 1 in 7,000 patients annually.
Semaglutide reduced heavy drinking days by 41% and total alcohol consumption by 70% in the first major trial for alcohol use disorder.
Night owls face higher migraine disability than early risers, new research shows, linking sleep timing to headache severity and functioning.
